Lilly announced the availability of lower-priced, non-branded versions of Humalog® Mix75/25™ KwikPen® (insulin lispro protamine and insulin lispro injectable suspension, 100 units/mL) and Humalog® Junior KwikPen® (insulin lispro injection, 100 units/mL).
The Insulin Lispro Injectable Suspension Mix75/25 KwikPen® (100 units/mL) and the Insulin Lispro Injection Junior KwikPen® (100 units/mL) are identical to the branded versions, but with different packaging and a 50% lower list price of $265.20 for a package of 5 KwikPens. The Company also continues to offer Insulin Lispro Injection® (100 units/mL), which has been available since May 2019 at a 50% lower list price of $137.35 per vial and $265.20 for a package of 5 KwikPens.
Additionally, in response to the COVID-19 pandemic, the Company recently launched its Insulin Value Program to assist eligible patients with obtaining their monthly insulin for $35 in most cases. Patients can access the co-pay savings card by calling the Lilly Diabetes Solution Center at (833) 808-1234. Medicare/Medicaid patients or those under similar federal or state programs are not eligible for this savings program due to federal guidelines.
The Company is also offering other affordability options to help with costs, including free insulin for individuals with minimal or no income.
“Out-of-pocket costs for insulin vary significantly depending on a person’s insurance coverage design. It’s important that we fill gaps in the healthcare system, including for people who use Medicare Part D and are unable to use the savings cards in our program,” said Mike Mason, president, Lilly Diabetes.
For more information visit lillydiabetes.com.
This article originally appeared on MPR